Table 2.
Baseline Demographic and Clinical Characteristics of Pediatric Trial Patients: Jos University Teaching Hospital and Comprehensive Health Centre Zamko
| JUTH Pediatric |
CHCZ Pediatric |
All Pediatric |
|||||
|---|---|---|---|---|---|---|---|
| Characteristic | POC (N = 14), n (%)a | SOC (N = 14), n (%) | POC (N = 9), n (%) | SOC (N = 8), n (%) | POC (N = 23), n (%) | SOC (N = 22), n (%) | PValueb (JUTH vs CHCZ) |
| Age, years | |||||||
| <5 | 4 (28.6) | 4 (28.6) | 2 (22.2) | 6 (75.0) | 6 (26.1) | 10 (45.5) | .077 |
| 5–9 | 5 (35.7) | 5 (35.7) | 6 (66.7) | 2 (25.0) | 11 (47.8) | 7 (31.8) | |
| 10–17 | 5 (35.7) | 5 (35.7) | 1 (11.1) | 0 (0.0) | 6(26.1) | 5 (22.7) | |
| Female sex (vs male) | 8 (57.1) | 8 (57.1) | 6 (66.7) | 1 (12.5) | 14 (60.9) | 9 (40.9) | .365 |
| World Health Organization clinical stage | |||||||
| 1 | 7 (70.0) | 6 (54.5) | 4 (50.0) | 3 (37.5) | 11 (61.1) | 9 (47.4) | .545 |
| 2 | 3 (30.0) | 2 (18.2) | 4 (50.0) | 2 (25.0) | 7 (38.9) | 4 (21.1) | |
| 3 | 0 (0.0) | 3 (27.3) | 0 (0.0) | 2 (25.0) | 0 (0.0) | 5 (26.3) | |
| 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (12.5) | 0 (0.0) | 1 (5.3) | |
| Tuberculosis coinfection | 0 (0.0) | 2 (14.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (9.1) | .519 |
| Weight-for-age (z score) | |||||||
| Wasted: less than -2SD | 3 (21.4) | 1 (7.1) | 0 (0.0) | 0 (0.0) | 3 (20.0) | 1 (6.3) | 1 |
| Normal: −2SD to +2SD (<5 years); −2SD to +1SD (≥5 years) | 9 (64.3) | 12 (85.7) | 1 (100) | 2 (100) | 10 (66.7) | 14 (87.5) | |
| Overweight: greater than +2SD (<5 years); greater than +1SD (≥5 years) | 2 (14.3) | 1 (7.1) | 0 (0.0) | 0 (0.0) | 2 (13.3) | 1 (6.3) | |
| Viral load, copies/mL | |||||||
| <10 000 | 2 (14.3) | 2 (14.3) | 2 (33.3) | 2 (28.6) | 4 (20.0) | 4 (19.1) | .039 |
| 10 001–99 999 | 6 (42.9) | 4 (28.6) | 2 (33.3) | 3 (42.9) | 8 (40.0) | 7 (33.3) | |
| 100 000–999 999 | 6 (42.9) | 8 (57.1) | 1 (16.7) | 1 (14.3) | 7 (35.0) | 9 (42.9) | |
| ≥1 000 000 | 0 (0.0) | 0 (0.0) | 1 (16.7) | 1 (14.3) | 1 (5.0) | 1 (4.8) | |
| Initial antiretroviral therapy regimen | |||||||
| ABC-3TC-EFV | 0 (0.0) | 1 (7.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (4.6) | <.001 |
| ABC-3TC-LPV/r | 2 (14.3) | 3 (21.4) | 2 (22.2) | 0 (0.0) | 4 (17.4) | 3 (13.6) | |
| AZT-3TC-EFV | 5 (35.7) | 7 (50.0) | 0 (0.0) | 1 (12.5) | 5(21.7) | 8 (36.4) | |
| AZT-3TC-LPV/r | 0 (0.0) | 0 (0.0) | 3 (33.3) | 2 (25.0) | 3 (13.0) | 2 (9.1) | |
| AZT-3TC-NVP | 3 (21.4) | 1 (7.1) | 4 (44.4) | 5 (62.5) | 7 (30.4) | 6 (27.3) | |
| TDF-3TC-DTG | 2 (14.3) | 2 (14.3) | 0 (0.0) | 0 (0.0) | 2 (8.7) | 2 (9.1) | |
| TDF-3TC-EFV | 2 (14.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (8.7) | 0 (0.0) | |
Abbreviations: 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; CHCZ, Comprehensive Health Centre Zamko; DTG, dolutegravir; EFV, efavirenz; IQR, interquartile range;JUTH, Jos University Teaching Hospital; LPV/r, lopinavir/ritonavir; NVP, nevirapine; POC, point of care; SD, standard deviation; SOC, standard of care; TDF, tenofovir.
a
Values shown are n (%) unless otherwise indicated; % is of those with recorded value.
b
The Fisher exact test was used to obtain P values for comparisons between the JUTH and CHCZ clinics.